2021-11-17T23:58:42-06:00 2020-12-31 861065772 Deloitte Tax LLP 695 Town Center Drive Suite 1200 Costa Mesa CA 926261924 990 2020-01-01 330328688 La Jolla Institute for Immunology LAJO 8587526500 9420 Athena Circle La Jolla CA 920371387 Richard Stryjewski CFO 8587526500 2021-11-17 1 Richard Stryjewski 999009999 John W Sadoff Jr P00540589 7144367100 2 AAL1 IAL1 2020 2022-09-23 18:48:47Z Richard Stryjewski 9420 Athena Circle La Jolla CA 920371387 80623646 0 X www.lji.org X 1988 CA Biomedical research dedicated to improving human health through studies of the immune system. 26 25 478 84 527258 150216 58096830 67178581 7349335 11469412 1740790 593426 1455500 1382227 68642455 80623646 769190 1119601 0 0 34553331 36998175 0 0 1088501 34836716 43052265 70159237 81170041 -1516782 -546395 50722461 60537089 27233372 37594395 23489089 22942694 X At La Jolla Institute for Immunology, our scientists focus on understanding how the immune system works in order to promote human health and prevent disease. Our discoveries apply to many diseases, ranging from diabetes to heart disease, infectious diseases to cancer. 0 0 71726530 1119601 11469412 The La Jolla Institute for Immunology ("LJI") is a private, nonprofit medical research organization and global leader committed to advancing our understanding of the power of the immune system. Through collaboration and creativity, LJI applies that knowledge toward the goal of Life Without Disease. The Institute is home to 20 independent laboratories, each operated by a leading scientist dedicated to shining light on an important aspect of the immune system. Our faculty lay the foundation for better treatments for a wide range of diseases and train the next generation of scientists to be pioneers in the field. 71726530 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 1 1 0 0 0 0 0 0 0 0 0 0 1 150 0 1 478 1 1 1 0 0 0 0 0 0 0 0 0 0 0 X 26 25 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AK AL AR CA FL GA HI IL KS KY MA MD MI MN MS NC NH NJ NM NY OH OR PA RI SC TN TX UT VA WI WV X Richard Stryjewski 8587526500 9420 Athena Circle La Jolla CA 920371387 Mitchell Kronenberg President & CSO 40.00 0.00 X X 580450 0 77787 Anthony Carr Director 2.00 0.00 X 0 0 0 Barton J Cohen Director 2.00 0.00 X 0 0 0 David A Brenner MD Director 2.00 0.00 X 0 0 0 David Dominguez Director 2.00 0.00 X 0 0 0 David M Rickey Director (Start 02/27/2020) 2.00 0.00 X 0 0 0 David R Webb PhD Director 2.00 0.00 X 0 0 0 Eric V Zwisler Director 2.00 0.00 X 0 0 0 Franois Ferr PhD Director 2.00 0.00 X 0 0 0 Gail K Naughton PhD Director 2.00 0.00 X 0 0 0 Genevive T Jacobs Director 2.00 0.00 X 0 0 0 Hunt Pettit Director 2.00 0.00 X 0 0 0 J Mark Waxman JD Director (Start 02/27/2020) 2.00 0.00 X 0 0 0 John E Major Chair Director (End 05/29/2020) 2.00 0.00 X 0 0 0 Kristine Charton JD Director 2.00 0.00 X 0 0 0 Larry S Spitcaufsky Director 2.00 0.00 X 0 0 0 Lynda Stuart MD PhD Director 2.00 0.00 X 0 0 0 Mark V Bowles Director 2.00 0.00 X 0 0 0 Michael D Coit Director 2.00 0.00 X 0 0 0 Mitsuo Satoh PhD Director 2.00 0.00 X 0 0 0 Pamela K Wasserman MPH Director 2.00 0.00 X 0 0 0 Paul Thiel Director 2.00 0.00 X 0 0 0 Richard S Bodman Director 2.00 0.00 X 0 0 0 Robert C Dynes PhD Director 2.00 0.00 X 0 0 0 Robert W Mahley MD PhD Director 2.00 0.00 X 0 0 0 Sandor W Shapery JD Director 2.00 0.00 X 0 0 0 Thomas L Tullie Director 2.00 0.00 X 0 0 0 Vanessa V Wertheim PhD MBA RN Director (End 05/19/2020) 2.00 0.00 X 0 0 0 Michael Dollar CFO 40.00 0.00 X 283029 0 48165 Stephen Wilson EVP, COO & CTO 40.00 0.00 X 442704 0 100765 Michael Croft Division Head/Professor 40.00 0.00 X 333908 0 72831 Alessandro Sette Division Head/Center Head/Prof 40.00 0.00 X 524511 0 98265 Erica Saphire Professor 40.00 0.00 X 387759 0 67026 Catherine Hedrick Professor 40.00 0.00 X 334888 0 69759 Klaus Ley Division Head/Professor 40.00 0.00 X 316999 0 59055 Stephen P Schoenberger Professor 40.00 0.00 X 277591 0 78300 3481839 0 671953 69 0 1 0 A&A Labs LLC 9863 Pacific Heights Blvd Ste F San Diego CA 92121 Lab supplies 827576 Pestotnik LLP 501 West Broadway Ste 1025 San Diego CA 92101 Legal services 412210 Zalgen Labs LLC 20271 Goldenrod Ln Suite 2083 Germantown MD 20876 AB services 328339 1903 Solutions LLC 2549 Eastbluff Dr Ste 378 Newport Beach CA 92660 Computer hardware and security 174164 ML Weekes & Company PC 800 Village Walk 166 Guilford CT 06437 Consulting 163452 10 33524 41761831 25383226 67178581 Consortium Revenue 900099 11469412 11469412 11469412 389971 389971 201770 201770 203455 0 203455 203455 203455 Building Management 531312 286454 286454 Technical Services 541900 240804 240804 Contract Service 900099 177001 177001 476198 476198 1180457 80623646 11469412 527258 1448395 27995 27995 1091606 1091606 1939639 1640307 253383 45949 26753215 22671916 3457725 623574 2750051 2355512 326312 68227 3601129 3033690 468255 99184 1954141 1673788 231872 48481 847522 104921 742601 401864 401864 949356 793871 90174 65311 679769 366669 307844 5256 140045 63981 39965 36099 1911754 1810526 91909 9319 8351070 7569655 741359 40056 188406 174129 8669 5608 65883 45217 17786 2880 4108625 4108625 287102 260113 25604 1385 Lab Supplies Service 11986207 11912973 73234 Consortium 9651554 9651554 Manuscripts Costs 1876795 774294 1065329 37172 Other Expenses 1606313 1595188 11125 81170041 71726530 8355010 1088501 0 0 7517882 13205247 14223696 14085143 17858 288077 1008011 869521 949703 1282772 42282604 23652426 17750709 18630178 9254602 12176151 50722461 60537089 16281365 17515141 3213029 5243053 7738978 14836201 27233372 37594395 X 15627555 10985160 7861534 11957534 23489089 22942694 50722461 60537089 -546395 0 X 0 1 X 1 1 1 X Th University of California San Diego San Diego CA RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 72328 72328 0 9455024 4878361 4576663 32740252 18701737 14038515 15000 15000 18630178 X 80624000 354 354 80623646 0 80623646 81170000 -41 -41 81170041 0 81170041 Part X, Line 2: The Institute is subject to federal and state income taxes on unrelated business income as defined under IRC Sections 511 through 515. For each of the years ended December 31, 2020 and 2019, taxes are recorded when paid and no provision for income tax has been made. The Institute had no unrecognized tax benefits or liabilities as of December 31, 2020 and 2019. Part XI, Line 2d - Other Adjustments: Rounding 354. Part XII, Line 2d - Other Adjustments: Rounding -41. South America 0 0 Program Services Research 46210 Sub-Saharan Africa 0 0 Program Services Research 5537 North America 0 0 Program Services Research 49278 Europe (Including Iceland & Greenland) 0 0 Program Services Research 404580 Europe (Including Iceland & Greenland) 0 0 Program Services Research 107181 Europe (Including Iceland & Greenland) 0 0 Program Services Research 77618 Europe (Including Iceland & Greenland) 0 0 Program Services Research 163243 Europe (Including Iceland & Greenland) 0 0 Program Services Research 34969 Europe (Including Iceland & Greenland) 0 0 Program Services Research 202990 0 0 0 0 0 0 888616 202990 1091606 0 0 0 0 0 0 Part I, Line 2: Detailed invoices are received, compared to budgeted subcontract amounts, and approved, prior to payment by LJI faculty. LJI may request additional detail or support for any unusual items. Additionally, scientific reports from subcontractors are received and reviewed by LJI investigators. Part III Accounting Method: Part I, Line 3, Column (F): Accrual method 1 0 0 Part I, Line 2: LJI supports certain charities whose mission is inline with our research. This support is not in the form of grants, but rather contributions. Therefore, documentation exists over payment of contributions. Formal monitoring and selections procedures not considered necessary. X X X X 0 0 0 0 0 0 0 0 0 Mitchell Kronenberg President & CSO 552665 0 19000 0 8785 0 62250 0 15537 0 658237 0 0 0 Alessandro Sette Division Head/Center Head/Prof 476660 0 43092 0 4759 0 62250 0 36015 0 622776 0 0 0 Stephen Wilson EVP, COO & CTO 420490 0 20075 0 2139 0 62032 0 38733 0 543469 0 0 0 Erica Saphire Professor 351366 0 0 0 36393 0 42750 0 24276 0 454785 0 0 0 Michael Croft Division Head/Professor 330667 0 0 0 3241 0 50213 0 22618 0 406739 0 0 0 Catherine Hedrick Professor 317362 0 0 0 17526 0 48299 0 21460 0 404647 0 0 0 Klaus Ley Division Head/Professor 312240 0 0 0 4759 0 46933 0 12122 0 376054 0 0 0 Stephen P Schoenberger Professor 274917 0 0 0 2674 0 42443 0 35857 0 355891 0 0 0 Michael Dollar CFO 239794 0 19500 0 23735 0 20085 0 28080 0 331194 0 0 0 SEE PART V X 350000 288077 0 1 1 288077 SEE PART V 0 Sch L, Part II, Loans to and / or From Interested Persons: (a) Name of Person: Erica Saphire(b) Relationship Between Interested Person and Organization:Highest Compensated Employee(c) Purpose of Loan: Faculty Housing Loan(d) Loan to or From the Organization: From(e) Original Principal Amount $350,000(f) Balance Due: $288,077(g) In Default: No(h) Approved by board or Committee: Yes(i) Written Agreement: Yes Sch L, Part IV, Business Transactions Involving Interested Persons: (a) Name of Person: Hilde Cheroutre(b) Relationship Between Interested Person and Organization: Spouse of President and CSO (c) Amount of Transaction: $303,284(d) Description of Transaction: Full Time Employee(e) Sharing of Organization Revenues?: No(a) Name of Person: Substantial Contributor(b) Relationship Between Interested Person and Organization: Substantial Contributor to the Organization.(c) Amount of Transaction: $3,421,688(d) Description of Transaction: Research Funding, Facility Rent, Cost Reimbursements (e) Sharing of Organization Revenues?: No Form 990, Part III, Line 4a In January 2020, before the first COVID-19 cases reached the United States, scientists at LJI began studying T cell reactivity to the SARS-CoV-2 virus. Their work gave the world early evidence that the immune system could indeed fight off the virus, offering hope that a vaccine could be effective. LJI Professors Alessandro Sette, Dr.Biol.Sci., and Shane Crotty, Ph.D., continued this groundbreaking and urgent research throughout 2020. Their labs were the first to share a detailed analysis of the body's adaptive immune response to the virus. Importantly, they showed that people who had previously had common cold coronaviruses had "cross-reactive" T cells that recognized SARS-CoV-2. Their labs also found that a dysfunctional T cell response could explain why the huge variation in COVID-19 outcomes, especially in the elderly. By March 2020, LJI had become a hub for COVID-19 studies, and LJI Professor Erica Ollmann Saphire, Ph.D., launched the Coronavirus Immunotherapeutic Consortium (CoVIC), with backing from the Bill & Melinda Gates Foundation. With more than 50 different efforts currently underway to find therapeutic antibodies across the globe, CoVIC provides a concerted and coordinated effort to compare these antibody candidates side by side under standardized criteria ultimately determining which ones are most likely to protect people and why. Work between the Saphire Lab and researchers at Los Alamos National Laboratory also gave us an early look at how SARS-CoV-2 was mutating as it spread across the globe, alerting many to the development of viral variants. Across the Institute, teams teased apart aspects of SARS-CoV-2. A team of postdoctoral researchers took a comprehensive look at SARS-CoV-2 and what lessons could be applied from the SARS and MERS outbreaks. LJI Professor Bjoern Peters, Ph.D., led a team to investigate the link between BCG vaccination and lower SARS-CoV-2 mortality rates in some countries. The BCG project showed that prior BCG vaccination did not seem to protect against SARS-CoV-2. It was a discouraging finding, but an important clue to how the virus was spreading around the world. In July 2020, Anthony Fauci, M.D., Director of the National Institute of Allergy and Infectious Diseases, came with an LJI study in hand when he testified before a House subcommittee on the nation's COVID-19 response on July 31. Holding up the Cell study, he called the T cell research from the labs of Sette and Crotty, "work we really need to pursue. We're just at the cusp of really understanding the importance of this type of response in COVID." Honors and Accomplishments In recognition of the impact of their peer-reviewed studies, LJI Professors Shane Crotty, Ph.D., Alessandro Sette, Dr. Biol.Sci., and Bjoern Peters, Ph.D., were named "Highly Cited Researchers" by Clarivate for 2020. This accolade means Crotty, Peters and Sette were in the top 1% of citations for their field of study between 2009 and 2019. Early in the pandemic, the Sette Lab received $500,000 in funding from the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, for research into immune responses to SARS-CoV-2. NIAID awarded more than $6.4 million to Erica Ollmann Saphire, Ph.D., professor at La Jolla Institute for Immunology (LJI), to support research toward COVID-19 antibody therapeutics. With this funding, The Coronavirus Immunotherapeutic Consortium (CoVIC) partnered with NIAID to provide independent evaluation of antibody therapeutics as part of the federal government's Operation Warp Speed. The funding to LJI is fueling ongoing efforts by CoVIC, led by Saphire, to analyze virus-fighting antibodies and track how the novel coronavirus may attempt to escape those antibodies. Saphire also received a $1 million gift from GHR Foundation, an independent global philanthropy based in Minneapolis, MN, to support CoVIC LJI Research Assistant Professor Daniela Weiskopf, Ph.D., was granted $1.4 million from the National Institutes of Health's National Cancer Institute (NCI) to examine the immune response to SARS-CoV-2 in study volunteers from Puerto Rico, where at least 75 percent of the population identifies as Hispanic or Latino. Research into this demographic is critical because the CDC reported that Hispanic and Latino Americans have been hospitalized with COVID-19 at more than four times the rate of white Americans. The five-year project is part of NCI's Serological Sciences Network (SeroNet), the largest coordinated effort to study immunology and COVID-19 in the United States. LJI Professor Catherine C. Hedrick, Ph.D., received $523,914 in funding from the National Institutes of Health's National Heart, Lung, and Blood Institute (NHLBI) to study how immune cells may contribute to cardiovascular problems in COVID-19 patients. Hedrick's work will focus on how the SARS-CoV-2 virus may affect monocytes, a type of immune cell in the bloodstream. LJI Instructor Alba Grifoni, Ph.D., received the Embassy of Italy Award to Honor Young Italian Researchers for Research to Fight COVID-19 from the Italian Scientists and Scholars in North America Foundation (ISSNAF). The award honors Grifoni's significant advances in understanding how the immune system responds to SARS-CoV-2, the virus that causes COVID-19. A team of LJI scientists, led by Suzanne Alarcon, won the XPRIZE Rapid COVID Testing Competition. The team developed and successfully implemented a fast, inexpensive, saliva-based COVID-19 screen that allowed the Institute's laboratories to reopen safely in 2020. The team received $500,000 in guaranteed winnings and is eligible to receive $1 million total as they take steps to make their screening protocol widely available. At the same time, LJI researchers launched new investigations into health threats outside of COVID-19. NHLBI awarded more than $2.3 million to LJI Professor Klaus Ley, M.D., for a new investigation into how a family of molecules called integrins helps the body fight disease. The research could open the door to new cancer therapies or treatments for autoimmune diseases. Sette and LJI Research Assistant Professor Cecilia Lindestam Arlehamn, Ph.D., in a close collaboration with overall study leader Professor David Sulzer, Ph.D., of Columbia University, received $3.5 million as part of a team award from Aligning Science Across Parkinson's (ASAP) to support a three-year study into how immune cells may contribute to Parkinson's disease. In December 2020, Saphire was named Scientist of the Year by ARCS San Diego, a chapter of the Achievement Rewards for College Scientists (ARCS) Foundation. The annual award recognizes Saphire's breakthroughs in structural virology and her leadership of the Coronavirus Immunotherapy Consortium (CoVIC). Notable Research Results In 2020, LJI research teams made discoveries meriting publication in leading peer-reviewed scientific journals 205 papers in all, continuing a trend of very high productivity. Together, they illustrate the range and power of immunology research, the caliber of LJI's faculty and their impact on a broad group of human health issues. Some of the highlights among papers published in 2020 include: LJI Professor Michael Croft, Ph.D., showed a protein called TL1A drives fibrosis in several mouse models, triggering tissue remodeling and making it harder for lungs and airways to function normally. The research suggested that TL1A and its receptor on cells could be targets for therapeutics aimed at reducing fibrosis and tissue remodeling in patients with severe lung disease. LJI Associate Professor Sujan Shresta, Ph.D., found that antibodies against Japanese encephalitis virus (JEV) are "cross-reactive and can also recognize Zika virus. Unfortunately, these antibodies can actually make Zika cases more severe. The research, conducted in mice, is the first to show that T cells can counteract this dangerous phenomenon. A separate Zika study from the Shresta Lab showed that the immune system's T cells have the power to prevent Zika infection in mice. This finding suggests that effective Zika vaccines need to activate T cells to work alongside antibodies. The lab of LJI Professor Klaus Ley, M.D., uncovered an additional role for T cells in atherosclerosis. Ley reported that certain T lymphocytes that start out trying to fight the disease can end up increasing inflammation and making atherosclerosis cases even worse. In the field of allergy research, Grgory Seumois, Ph.D., instructor and director of LJI's Sequencing Core, and LJI Professor Pandurangan Vijayanand, M.D. Ph.D., uncovered a clue to why non-allergic people don't have a strong reaction to house dust mites. They found a previously unknown subset of T cells that may control allergic immune reactions and asthma from ever developing in response to house dust mitesand other possible allergens. Form 990, Part III, Line 4a The Croft Lab reported a potential way to stop asthma attacks in the first place. The researchers discovered that blocking two immune molecules, called OX40L and CD30L, at the same time is key to preventing asthma attacks in a mouse model. The research points to a way to achieve a strong, long-lasting reduction in asthma exacerbations. The Sette Lab uncovered further evidence linking autoimmunity to the onset of Parkinson's disease. In fact, the researchers report that signs of autoimmunity can appear in Parkinson's disease patients years before their official diagnosis. The research could make it possible to someday detect Parkinson's disease before the onset of debilitating motor symptoms. Also in the field of autoimmunity research, LJI Associate Professor Sonia Sharma, Ph.D., showed that a previously poorly understood enzyme actually inhibits inflammation in blood vessels. The research offers a potential path to treating DADA2, an inflammatory blood vessel disease in children that is similar to Kawasaki disease. In two separate studies, LJI Professor Matthias von Herrath, M.D., uncovered important clues to explain the root of type 1 diabetes. In one study, his lab used a mouse model to suggest that blocking nerve signals to the pancreas could stop patients from ever developing type 1 diabetes. In a second study, the lab found that even healthy people have potentially harmful T cells lurking in the pancreasin surprisingly high numbers. These results add evidence for the theory that type 1 diabetes is not caused by malfunctioning T cells attacking beta cells. LJI scientists also led foundational research into the inner workings of immune cells. LJI Professor Stephen P. Schoenberger, Ph.D., discovered a protective biological switch that, briefly, turns on the immune response at the first whiff of an invaderan important featurebut can also turn off potentially destructive immune rampage that may also occur. This "off" switch can protect against serious, life threatening inflammation. LJI Professor Shane Crotty, Ph.D., investigated how a protein called Bcl6 works as a "master regulator" in the immune system. The research is an important step toward designing vaccines and therapies that can "switch on" the immune cells that help produce disease-fighting antibodies. LJI Professor Catherine C. Hedrick, Ph.D., tracked down the rare stem cells that generate neutrophils in human bone marrow. This research gives scientists a potential path for intervening in diseases where neutrophil development goes awry. LJI Instructor Alex Marki, M.D., and Dr. Ley found that people with sepsis have never-before-seen particles in their blood. The scientists are the first to show that these particles, called elongated neutrophil-derived structures (ENDS), break off of immune cells and change their shape as they course through the body. The Vijayanand Lab also created 3D maps of how enhancer sequences and genes interact in several types of immune cells. Their study opened the door to understanding individual risk for diseases from asthma to cancer. Competitive Research Grant Funding & Research Awards & Distinctions AbViro, LLC, Albert Einstein College of Medicine, American Association for Cancer Research, American Association of Laboratory Animal Science, American Heart Association, Ann & Robert H. Lurie Children's Hospital of Chicago, Bill and Melinda Gates Foundation, Boston Children's Hospital, Bristol Myers Squibb, Cancer Research Institute, Cedars-Sinai Medical Center, Celsense Inc., Chan Zuckerberg Initiative, Chicago BioSolutions, Columbia University, CRDF Global, Crohn's and Colitis Foundation, Cue Biopharma, Inc., Eli Lilly and Company, Emergent Ventures, Emory University, European Commission, GHR Foundation, Gossamer Bio, Gritstone Bio, Halozyme, Inc., Histogen, Inc., Human Vaccines Project, Icahn School of Medicine at Mount Sinai, Integrated Biotherapeutics, International AIDS Vaccine Initiative, Intrepida Bio, Kyowa Kirin Co., Ltd, Kyowa Kirin Pharmaceutical Research, Inc., Leukemia & Lymphoma Society, Lyell Immunopharma, Massachusetts Institute of Technology , National Institute for Biotechnology, National Institutes of Health, Naval Medical Research Center, Navigate BioPharma Services, Inc., Nektar Therapeutics, Novo Nordisk, Oregon health and Science University, Pfizer, Regeneron Pharmaceuticals, Inc., Research Foundation for Mental Hygiene, Inc., Sorrento Therapeutics, Takeda Pharmaceutical Company, The Michael J. Fox Foundation, The Scripps Research Institute, The Washington University, Tremeau Pharmaceuticals, Inc., Tulane University, Turnstone Biologics, Ukko Inc., University of California Berkeley, University of California Irvine, University of California Riverside, University of California San Diego, University of Oxford, University of Pennsylvania, University of Puerto Rico Medical Sciences Campus, University of Wisconsin, Vanderbilt University, Victoria University, Washington University in Saint Louis, Zalgen Labs, LLC. Form 990, Part VI, Section B, line 11b A draft of the Form 990 is provided to all board members prior to the electronic filing of the tax return. Form 990, Part VI, Section B, line 12c The Institute administers three separate conflict of interest policies applying to 1) The Board of Directors, 2) Faculty and Senior Administration, and 3) An investigator financial conflict of interest policy required under National Institutes of Health Regulations. The Institute regularly and consistently monitors and enforces these policies in accordance with written procedures, which include the completion of disclosure forms by covered individuals, evaluation of completed forms by a designated conflict review officer, and as necessary, further evaluation and determination by a designated conflict review committee. If a conflict is determined, a management plan is designed and monitored for the specific situation. Such plan may require the covered individual to eliminate the conflict. Form 990, Part VI, Section B, line 15 Compensation decisions for the institute's CEO and other key employees are made annually. Adjustments, if any, typically take effect on a January 1st cycle. For these purposes, the institute's Human Resources Department obtains relevant market comparability data for each position on an annual basis. In accordance with its charter, the compensation committee of the board of directors reviews and discusses this information, and the performance of the institute's CEO and key employees, and formulates recommended compensation actions to the full board of directors. The board of directors reviews these recommendations and related information in deciding compensation levels for each position. Form 990, Part VI, Section C, line 19 The Institute makes its governing documents, Conflict of Interest Policy, and Financial Statements available to the public upon request.